Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis
Mosler P, Sherman S, Marks J, Watkins JL, Geenen JE, Jamidar P, Fogel EL, Lazzell-Pannell L, Temkit M, Tarnasky P, Block KP, Frakes JT, Aziz AA, Malik P, Nickl N, Slivka A, Goff J, Lehman GA. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointestinal Endoscopy 2005, 62: 245-250. PMID: 16046988, DOI: 10.1016/s0016-5107(05)01572-5.Peer-Reviewed Original ResearchConceptsPost-ERCP pancreatitisOral allopurinolAllopurinol groupControl groupOxygen-derived free radical productionPlacebo 4 hoursProcedure risk factorsCommon major complicationSeverity of pancreatitisFree radical productionProphylactic allopurinolPatient demographicsMajor complicationsOverall incidencePostprocedure pancreatitisPharmacologic agentsRisk factorsPancreatitisPatientsStandardized criteriaAllopurinolERCPSeveritySignificant differencesIncidence